Exploring the novel role and mechanistic insights of skeletal muscle relaxant cyclobenzaprine hydrochloride in esophageal squamous cell carcinoma treatment
Flexeril exhibits anti-cancer effects in ESCC by inhibiting the JAK1-STAT3-WDHD1 axis and inducing DDR. These findings suggest that Flexeril may serve as a potential novel therapeutic agent for the treatment of ESCC.
Authors
- Qiang Ma (ORCID: https://orcid.org/0000-0002-6379-9927)
- Maoju Tang
- Xiaolan Guo (ORCID: https://orcid.org/0000-0003-2948-8997)
- Jibing Cheng
- Xiaowu Zhong (ORCID: https://orcid.org/0000-0001-5143-5838)
- Caizhi Liao (ORCID: https://orcid.org/0000-0003-1271-3027)
- Lei Xu (ORCID: https://orcid.org/0000-0002-9241-7019)
- Xiao Liu (ORCID: https://orcid.org/0000-0001-5136-7425)
- Yong Yang
- Man Luo (ORCID: https://orcid.org/0000-0003-2393-102X)
Institutions
- North Sichuan Medical University (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1016/j.ejps.2025.107051
- Citations
- 3
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 4.41